Printer Friendly

IMREG SIGNS LETTER OF INTENT WITH JIANGXI GANNAN PHARMACEUTICAL FACTORY OF THE PEOPLE'S REPUBLIC OF CHINA

 NEW ORLEANS, La., June 3 /PRNewswire/ -- IMREG, Inc. (OTC Bulletin Board Symbol: IMRGA) announced today that it has signed a letter of intent with the JiangXi Gannan Pharmaceutical Factory of the People's Republic of China to develop a joint venture between the two companies for manufacturing, clinical testing, and marketing of IMREG(R)-1 in China and other Pacific Rim countries, excluding Japan. IMREG(R)-1 is an immunoregulator currently under development in the United States by IMREG, Inc.
 Under the proposed joint venture, IMREG's Chinese partner will manufacture IMREG(R)-1 and provide the funds for the costs of manufacturing, clinical testing, and obtaining marketing approval for IMREG(R)-1 in the aforementioned countries. The joint venture contemplates a sharing of net profits from sales in these countries, and is subject to negotiation of final agreements.
 IMREG(R)-1 is a biopharmaceutical which is recovered from a subfraction of white blood cells (leukocytes) known as a leukocyte dialyzate. Leukocyte dialyzates, similar to those employed by IMREG, Inc. as a source of IMREG(R)-1, are used in China for the treatment of several infectious conditions including hepatitis and herpes. These leukocyte dialyzates are produced by the JiangXi Gannan Pharmaceutical Factory and are marketed throughout China by its network of 700 sales outlets.
 "The proposed joint venture represents an important initiative through which our American biomedical technology coupled with the opportunities provided by our Chinese partner can lead to potential improvement in therapy and provides a pathway for the entry of our products into China and other countries in the Pacific Rim. The objective of our joint therapeutic approach is to modify the immune system to the patient's advantage. We are quite excited about the prospect of engaging our Chinese colleagues in this biomedical initiative at a time of rapid economic development and change in China. We, of course, are continuing to pursue regulatory approval for marketing of the IMREG(R)-1 biopharmaceutical in the U.S.," said Dr. A. Arthur Gottlieb, president and scientific director of IMREG, Inc.
 The immunologic properties of leukocyte dialyzates were originally reported in the American medical literature in the 1950s. An analysis of such leukocyte derived subfractions by scientists at IMREG, Inc. led to the isolation of IMREG(R)-1 and its subsequent clinical testing.
 IMREG(R)-1 is an investigational biopharmaceutical under development by IMREG, Inc., of New Orleans and Cambridge, Mass., as a potential therapeutic agent for the treatment of HIV diseases and other conditions which affect the immune system, or in which an altered immune system contributes to disease. The results of the first placebo-controlled clinical trial of IMREG(R)-1 in HIV disease were reported in the "Annals of Internal Medicine" in July, 1991. The IMREG(R)-1 biopharmaceutical is believed to exert several actions on the cell mediated immune system which is severely impacted in HIV disease and AIDS.
 -0- 6/3/93
 /CONTACT: Clifford H. Kern, III, Ph.D. of IMREG, Inc., 504-523-2875, or Steven F. Kessler of Howard Bronson & Company, Inc., 212-867-6160, for IMREG, Inc./


CO: IMREG, Inc. ST: Louisiana IN: MTC SU:

SM-OS -- NY018 -- 4841 06/03/93 09:47 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 3, 1993
Words:525
Previous Article:COOK COUNTY (ILL.) $130 MILLION TAX ANTICIPATION NOTES RATED 'F-1+' BY FITCH -- FITCH FINANCIAL WIRE --
Next Article:JCPENNEY SALES UP 2.5 PERCENT IN MAY
Topics:


Related Articles
IVAX FORMS JOINT VENTURE WITH CHINESE PHARMACEUTICAL FACTORY
GELMAN SCIENCES SIGNS LETTER OF INTENT TO CREATE JOINT-VENTURE COMPANY IN PEOPLE'S REPUBLIC OF CHINA
CAMBREX CORPORATION'S JOINT VENTURE IN CHINA
CAMBREX CORPORATION'S JOINT VENTURE IN CHINA
CELCOR INC. ANNOUNCES PLAN TO ACQUIRE NORTHEAST (USA) CORP.
CELCOR INC. ANNOUNCES PLAN TO ACQUIRE NORTHEAST (USA) CORP.
UNIGENE SIGNS LETTER OF INTENT FOR CALCITONIN JOINT VENTURE IN CHINA
UNIGENE SIGNS LETTER OF INTENT FOR CALCITONIN JOINT VENTURE IN CHINA
SMITHKLINE BEECHAM TO INTRODUCE HAVRIX, HEPATITIS A VACCINE, IN THE PEOPLE'S REPUBLIC OF CHINA
HORIZON Pharmacies, Inc. Chief Executive Officer Interviewed By CEOcast.com.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters